CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 200 enrolled
Drug / intervention
Hybrid revascularization +1 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01035567
NCT01035567Phase 3Completed
CompareCT.gov

Prospective Randomised Pilot Study Evaluating the Safety and Efficacy of Hybrid Revascularization in Multivessel Coronary Artery Disease

Silesian Centre for Heart Diseases·interventional·Posted Dec 18, 2009·Updated Dec 3, 2013

In Brief

A Phase 3 clinical trial evaluating Hybrid revascularization and Coronary Artery Bypass Grafting for Heart Disease and 3 related conditions. Completed, enrolled 200 participants across 2 sites.

Detailed Summary

The purpose of the study is to assess the safety and efficacy of hybrid revascularization in comparison with coronary artery bypass grafting among patients with multivessel coronary artery disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Disease, Myocardial Ischaemia, Coronary Disease, Coronary Artery Disease
CountriesPoland
CollaboratorsMinistry of Science and Higher Education, Poland

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 18, 2009
Enrollment StartNov 1, 2009
Primary CompletionMay 1, 2013
Study CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 16.5 years ago

Interventions

Hybrid revascularizationprocedure

First stage: implantation of the internal mammary artery into LAD in MIDCAB/TECAB procedure Second stage: PCI with drug eluting stents in other coronary arteries qualified for revascularization within 36 hours after surgery

Coronary Artery Bypass Graftingprocedure

Coronary artery bypass grafting with sternotomy on or off the pump at discretion of the operator.